As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to
Today is set to kick off with a welcome chair of healthcare at Economist Impact, Vivek Muthu, followed by a keynote speech on ‘Cancer control: Global perspectives and European solutions’ by
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh